Free Shipping On Orders Over $1,000!

Separase (Ser1073) Polyclonal Antibody, ALEXA FLUOR® 647 Conjugated

Applications

  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Human
Overview
Catalog # bs-5304R-A647
Product Name Separase (Ser1073) Polyclonal Antibody, ALEXA FLUOR® 647 Conjugated
Applications IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Human
Specifications
Conjugation ALEXA FLUOR® 647
Host Rabbit
Source KLH conjugated synthetic phosphopeptide derived from human ESPL1 around the phosphorylation site of Ser1073
Modification Site Ser1073
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 9700
Subcellular location Cytoplasm, Nucleus
Synonyms Caspase like protein ESPL1; ESP 1; ESP1; ESP-1; ESPL 1; ESPL1; ESPL-1; Extra spindle poles like 1; Extra spindle poles like 1 protein; Separin; Similar to fission yeast cut1and gene; SSE; Separase; ESPL1_HUMAN.
Background Separase is a cysteine protease that is essential for mitotic progression by separating sister chromatids. Each cell must receive one chromatid of every chromosome, during mitosis. Cohesin plays an important role in cohering sister chromatids during the prophase through anaphase stages of mitosis, making certain that genomic information is replicated accurately. As the cellular division process continues, separase destroys cohesin by means of cleavage, allowing the chromatids to separate and divide with the cell. Separase activity is highly regulated. It not only cleaves cohesin at the onset of anaphase but also cleaves itself, promoting downregulation of separase after anaphase. Should a human cell become an aneuploid (one too many or too few chromatids), the embryo most likely will not survive. Should the embryo survive, it will most likely develop severe birth defects or later develop malignant cancers.
Application Dilution
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200